New hope for Hard-to-Treat endometrial cancer: phase 3 trial launches
NCT ID NCT07578649
First seen May 16, 2026 · Last updated May 16, 2026
Summary
This study tests a new experimental drug (PF-08634404) combined with chemotherapy against an approved drug (pembrolizumab) plus chemotherapy for adults with advanced or recurrent endometrial cancer that has a working DNA repair system (pMMR). About 600 women will be randomly assigned to one of the two treatment groups. The goal is to see if the new combination helps keep cancer from growing longer than the current standard treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.